Approval · Notice of Compliance 20655 · 2018
KAZANO: Notice of Compliance 20655
Issued March 23, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20655
- Date
- March 23, 2018
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to product monograph in response to health canada issued advisement letter
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| KAZANO | Not yet assigned | — |
Medicinal ingredients
- METFORMIN HYDROCHLORIDE 500 MG per MG
- ALOGLIPTIN BENZOATE 12.5 MG per MG
- METFORMIN HYDROCHLORIDE 850 MG per MG
- METFORMIN HYDROCHLORIDE 1,000 MG per MG